Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2025-01-03T14:53:40.178Z Has data issue: false hasContentIssue false
  • English
  • Français

Letter to the editor

Published online by Cambridge University Press:  18 September 2015

JA den Boer ,
HGM Westenberg ,
JW Louwerens  and
CJ Slooff
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letter
Information
Acta Neuropsychiatrica , Volume 4 , Issue 2 , June 1992 , pp. 46
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1992

References

Literatuur:

1.Reyntjens, A, Gelders, YG, Hoppenbrouwers, M-LJA, Bussche, G van den.Thymosthenic Effects of Ritanserin (R55667), a Centrally Acting Serotonin-S2 Receptor Blocker, Drug Dev Res 1986; 8: 205–11.CrossRefGoogle Scholar
2.Duinkerke, SJ, Botter, PA, Jansen, AAI, Dongen, PAM van, Haaften, AJ, Boom, AJ, Laarhoven, JHM van, Busard, HLSM.Ritanserin, a selective 5-HT2/1c-antagonist, reduces negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiat 1992: aangeboden voor publikatie.Google Scholar
3.Louwerens, JW, Coppens, HC, Korf, J, Slooff, CJ, Paans, AMG, Vaalburg, W.On the pathogenetic role of dopaminergic and serotonergic neurotransmission in longterm hospitalized psychotic patients. Schizoph Res 1990; 3: 53.CrossRefGoogle Scholar